Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Bacillus cereus Prolipoprotein diacylglyceryl transferase 2 (lgt2), partial CSB-YP758679BQN1
CSB-EP758679BQN1
CSB-BP758679BQN1
CSB-MP758679BQN1
CSB-EP758679BQN1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant HTH-type transcriptional regulator sgrR (sgrR), partial CSB-YP758680YAS
CSB-EP758680YAS
CSB-BP758680YAS
CSB-MP758680YAS
CSB-EP758680YAS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Membrane-bound lytic murein transglycosylase F (mltF) CSB-YP758681YAS
CSB-EP758681YAS
CSB-BP758681YAS
CSB-MP758681YAS
CSB-EP758681YAS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant tRNA threonylcarbamoyladenosine biosynthesis protein RimN (rimN) CSB-YP758682YAS
CSB-EP758682YAS
CSB-BP758682YAS
CSB-MP758682YAS
CSB-EP758682YAS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase (LYS5) CSB-YP758683DOT
CSB-EP758683DOT
CSB-BP758683DOT
CSB-MP758683DOT
CSB-EP758683DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii DASH complex subunit DAD4 (DAD4) CSB-YP758684DOT
CSB-EP758684DOT
CSB-BP758684DOT
CSB-MP758684DOT
CSB-EP758684DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii DNA damage checkpoint control protein MEC3 (MEC3) CSB-YP758685DOT
CSB-EP758685DOT
CSB-BP758685DOT
CSB-MP758685DOT
CSB-EP758685DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Mediator of RNA polymerase II transcription subunit 4 (MED4) CSB-YP758686DOT
CSB-EP758686DOT
CSB-BP758686DOT
CSB-MP758686DOT
CSB-EP758686DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Tethering factor for nuclear proteasome STS1 (STS1) CSB-YP758687DOT
CSB-EP758687DOT
CSB-BP758687DOT
CSB-MP758687DOT
CSB-EP758687DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii COPII coat assembly protein SEC16 (SEC16), partial CSB-YP758688DOT
CSB-EP758688DOT
CSB-BP758688DOT
CSB-MP758688DOT
CSB-EP758688DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Histone H2B.1 (HTB1) CSB-YP758689DOT
CSB-EP758689DOT
CSB-BP758689DOT
CSB-MP758689DOT
CSB-EP758689DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii GPI ethanolamine phosphate transferase 3 (GPI13), partial CSB-YP758690DOT
CSB-EP758690DOT
CSB-BP758690DOT
CSB-MP758690DOT
CSB-EP758690DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Genetic interactor of prohibitin 5, mitochondrial (GEP5) CSB-YP758691DOT
CSB-EP758691DOT
CSB-BP758691DOT
CSB-MP758691DOT
CSB-EP758691DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human immunodeficiency virus type 1 group M subtype C Virion infectivity factor (vif) CSB-YP758692HDAH
CSB-EP758692HDAH
CSB-BP758692HDAH
CSB-MP758692HDAH
CSB-EP758692HDAH-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii RNA exonuclease 3 (REX3) CSB-YP758693DOT
CSB-EP758693DOT
CSB-BP758693DOT
CSB-MP758693DOT
CSB-EP758693DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Nitrogen permease regulator 3 (NPR3), partial CSB-YP758694DOT
CSB-EP758694DOT
CSB-BP758694DOT
CSB-MP758694DOT
CSB-EP758694DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Glucose transport transcription regulator RGT1 (RGT1), partial CSB-YP758695DOT
CSB-EP758695DOT
CSB-BP758695DOT
CSB-MP758695DOT
CSB-EP758695DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Palmitoyltransferase ERF2 (ERF2), partial CSB-YP758696DOT1
CSB-EP758696DOT1
CSB-BP758696DOT1
CSB-MP758696DOT1
CSB-EP758696DOT1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Pre-mRNA-splicing factor CLF1 (CLF1), partial CSB-YP758697DOT
CSB-EP758697DOT
CSB-BP758697DOT
CSB-MP758697DOT
CSB-EP758697DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Ashbya gossypii Ubiquinone biosynthesis protein COQ4, mitochondrial (COQ4), partial CSB-YP758698DOT
CSB-EP758698DOT
CSB-BP758698DOT
CSB-MP758698DOT
CSB-EP758698DOT-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>